Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW

Clinical trial NCT06355609 · RECRUITING

Trial details

NCT number: NCT06355609
Sponsor: Hunan Province Tumor Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer

Start date: 2024-07-01
Primary completion: 2025-12-30
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.